Quest Diagnostics Declares Quarterly Cash Dividend

(NYSE:DGX) Quest Diagnostics announced that its Board of Directors has declared a quarterly cash dividend of $0.86 per share. The dividend will be payable on January 27, 2027. Shareholders of record as of January 10, 2027, will be eligible to receive the dividend. The announcement was made by Quest Diagnostics' Board of Directors. The company is a provider of diagnostic information services. The dividend declaration reflects the company's ongoing commitment to return value to its shareholders. The payment of the dividend is subject to the record date and payment date as specified. No other financial or operational figures were disclosed in this announcement. No executive names or additional commentary were included in the release. The notice pertains solely to the dividend declaration for the specified quarter.

Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI

(NYSE:DGX) Quest Diagnostics announced it is integrating its Haystack MRD ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR, an electronic health record from Flatiron Health, via a pilot program with American Oncology Network (AON) and other community oncology providers. The integration will enable 4,700 clinicians across the Flatiron network of 1,600 community-based cancer care locations in the United States to quickly access Quest services. Nearly 200 AON sites now have access to OncoEMR MPI and can use it to order the Quest tests, with AON representing more than 350 providers practicing across 21 states. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, with nearly 57,000 employees. The company's Comprehensive Genomic Profiling portfolio includes several panels that use advanced sequencing to identify up to 530 genes associated with therapy response. Quest plans to launch the full OncoEMR MPI integration to providers nationwide in the second half of the year. Last summer, the company began to offer its Haystack MRD test through the Epic Aura platform.

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

(NYSE: DGX) Quest Diagnostics announced that the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers. With this approval, Haystack MRD is now authorized for patient testing in all 50 U.S. states. The test has been available for clinician ordering since late 2024 in 49 states and the District of Columbia. Haystack MRD's clinical utility was demonstrated in a landmark study led by Dr. Andrea Cercek at Memorial Sloan Kettering Cancer Center and published in The New England Journal of Medicine in May 2025, where ctDNA testing identified clinical complete response at a median of 1.4 months, compared to more than 6 months using imaging methods. The FDA granted Haystack MRD Breakthrough Device Designation in 2025 for use in Stage II colorectal cancer. Haystack MRD is also available for clinical trials as an investigational device in laboratories located in Baltimore, Maryland; Hamburg, Germany; and Helsinki, Finland. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, with nearly 57,000 employees.

Quest Diagnostics (NYSE: DGX) announced that its Board of Directors has declared a quarterly cash dividend of $0.86 per share. The dividend will be payable on July 22, 2026, to shareholders of record of Quest Diagnostics common stock on July 8, 2026. Quest Diagnostics is described as a leader in diagnostic information services. The company serves half the physicians and hospitals in the United States and one in three American adults each year. Quest Diagnostics employs nearly 57,000 people. This dividend declaration reflects the company's ongoing commitment to returning value to shareholders. Investors should note the record and payment dates for the upcoming dividend.

Quest Diagnostics Prices $500 Million of Senior Notes

Quest Diagnostics Incorporated (NYSE:DGX) announced the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036. The company expects to receive the net offering proceeds upon closing on May 6, 2026, subject to customary closing conditions. The net proceeds are expected to be used for general corporate purposes, which may include the repayment of indebtedness, specifically its $500 million aggregate principal amount of 3.45% Senior Notes maturing on June 1, 2026. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year. The offering is being made under Quest Diagnostics' shelf registration statement.

QUEST DIAGNOSTICS INC